It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

GSK and Sanofi start phase 2 trial on refined Covid-19 vaccine

Mon 22 February 2021 11:05 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - GlaxoSmithKline and Sanofi have started a new clinical trial into their Cobid-19 vaccine candidate with the aim of refining the dosage.

The new second phase trial will enroll 720 volunteers, include older adults, and if the results are successful then a phase three trial will begin in the second quarter with deliveries possibly following in the final three months of 2021.

GSK President, Roger Connor, emphasised the ongoing need worldwide for multiple vaccines while expressing confidence in the firms' approach using a so-called 'adjuvant' and improved antigen formulation.

An earlier study in December showed the vaccine provoked an immune response among the participants aged 18-49 in the trial similar to that generated in volunteers who had recovered from Covid-19.

But among older patients the response was lower, likely due to an insufficient concentration of the antigen.

Second phase trials are designed to test the immune response of the human body triggered by a vaccine before moving to the next stage, which measures its actual efficacy among a larger sample of volunteers.

Work against the new strains of SARS-CoV-2, the disease that causes Covid-19, were also under way, the two companies said in a statement.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.

    More company news from ShareCast